Amgen’s Imdelltra Cut the Risk of Death by 58%. AMGN Had Already Climbed 17% From Its September Low.

Key Takeaways

• Amgen’s DeLLphi-305 data materially upgrade IMDELLTRA’s opportunity: adding it to IMFINZI reduced the risk of death by 58%, extended median overall survival to 21.1 months from 12.7 months, and kept nearly 80% of patients alive at one year versus 53% on IMFINZI alone.
• The market knew the trial had succeeded on September 8, but not the size of the benefit. AMGN has since risen 16.9% from its September 15 low and reached a record close before the full data became public, making the magnitude of the clinical result more important than the fact of success.
• The full data arrived on a Saturday, so Monday is the first session to trade on them. The stock goes in near its high, above its 50-day and 200-day averages, with on-balance volume falling and a consensus analyst target of $403.79 that sits below Friday’s $439.26 close.

The Clinical Result Is Large Enough to Change IMDELLTRA’s Commercial Address

The central fact is not simply that DeLLphi-305 met its endpoint. Amgen reported that IMDELLTRA, or tarlatamab, combined with AstraZeneca’s IMFINZI reduced the risk of death by 58% in first-line maintenance treatment for extensive-stage small cell lung cancer. The hazard ratio was 0.42, with median overall survival of 21.1 months compared with 12.7 months for IMFINZI alone.

That is a 8.4-month improvement in median survival, a substantial result in a disease setting where the median survival from the start of first-line maintenance is roughly one year. Nearly 80% of patients receiving the combination were alive at one year, versus 53% on IMFINZI alone. Progression-free survival also improved to 7.4 months from 1.9 months, meaning the benefit was visible both in delaying progression and in extending life.

The result matters commercially because it moves IMDELLTRA upstream. The drug is currently approved for patients whose small cell lung cancer progressed on or after platinum chemotherapy, but only about 40% of patients reach second-line treatment. A first-line maintenance role gives Amgen access to a much larger portion of the treatment journey, assuming the regulatory process supports that expansion.

The response was not limited to a narrow subgroup. Amgen reported benefit across prespecified groups, including patients with brain and liver metastases. That consistency is more valuable than a single headline hazard ratio because it reduces the risk that the result depends on an unusually favorable patient mix.

The safety trade-off is real but does not erase the efficacy signal. Treatment-related adverse events of Grade 3 or higher occurred in 20.9% of patients receiving the combination, versus 10.8% with IMFINZI alone. Cytokine release syndrome occurred in 49.6% of patients, although most cases were Grade 1, with 7.4% Grade 2 and one Grade 3 case. The likely commercial question is therefore not whether the drug works, but whether treatment centers can absorb the monitoring and administration burden at first-line scale.

The Cross-Trial Comparison Raises the Competitive Stakes

A cross-trial comparison is not a head-to-head result, but DeLLphi-305 still looks unusually strong beside the regimen already approved in this setting. Jazz Pharmaceuticals’ Zepzelca combined with Tecentriq produced a hazard ratio of 0.73 in the IMforte study, with median overall survival of 13.2 months versus 10.6 months for its control group.

DeLLphi-305’s hazard ratio of 0.42 is materially lower, and its 8.4-month median survival advantage is wider than IMforte’s 2.6-month advantage. Different control arms, patient populations, trial designs, and follow-up periods prevent a clean ranking of the two regimens. Still, the direction and scale of the difference give Amgen a credible efficacy argument in a market that already has an approved first-line maintenance option.

That distinction matters for valuation. If IMDELLTRA merely joined the first-line market with comparable efficacy, the opportunity would be incremental and competition could compress adoption. A result this strong gives oncologists a reason to reconsider the treatment sequence, particularly if the survival benefit remains durable with longer follow-up.

The result is not yet a completed commercial event. Amgen said it is moving quickly to share the data with regulators worldwide, but gave no filing date or regulatory timeline. The stock therefore has a powerful clinical proof point but not yet a confirmed first-line label, launch date, or estimate for how quickly treatment centers could adopt the combination.

The Stock Had Already Recovered Before Investors Saw the Magnitude

The timing creates the most important tension in the setup. On September 8, Amgen announced that DeLLphi-305 had met its primary overall-survival endpoint and showed significant progression-free-survival and response-rate gains. The company did not disclose the hazard ratio or survival medians at that time.

AMGN fell 10.1% that day to $393.17, not because the trial failed, but because Novartis reported disappointing cardiovascular-outcomes data for pelacarsen, which pressured expectations for Amgen’s olpasiran program. The stock then declined to a September 15 closing low of $375.65. From that low to Friday’s $439.26 close, AMGN gained 16.9%.

The market therefore knew the trial was positive while the stock was recovering from an unrelated pipeline shock. What remained unknown was whether the full data would show a modest benefit or a practice-changing one. The 58% reduction in mortality risk answers that question favorably, but the price had already returned to a record close of $447.28 on October 22 before the full data were released.

That distinction changes the trade. The clinical announcement supplies new information about magnitude, not direction. It can support a higher long-term estimate for IMDELLTRA, but it does not offer the same information advantage as a completely unexpected trial success.

The unresolved olpasiran issue also remains part of the valuation backdrop. Amgen has said its drug lowers lipoprotein(a) more than pelacarsen, but the outcome question is not expected to be settled until 2027 or later. The September selloff showed that investors are willing to revalue Amgen’s broader pipeline around a single late-stage outcome, even when another major program is producing positive data.

Amgen daily chart with technical signals, through the Oct 23 close

The Technical Picture Says Strong Longer Term, Tired Near Term

AMGN’s technical readings split cleanly between trend and timing. The stock is trading above its 50-day moving average of $417.26 and its 200-day moving average of $371.61, and its Kavout moving-average score is 100, the top reading. The price is also above volume-weighted average price, while the accumulation-distribution trend is rising.

Those readings describe a stock with a strong intermediate trend. Friday’s close was 5.3% above the 50-day average, and the price remains well above the 200-day average. A pullback that holds the 50-day line would therefore be consistent with consolidation inside an intact uptrend rather than an immediate reversal.

The shorter-term signals are less comfortable. The oscillator score was 37, while stochastic, StochRSI, Williams percent range, and the commodity channel index were all in oversold territory. At the same time, the trend-strength reading had turned bearish, the supertrend tool generated a sell signal, the price channel was breaking down, and on-balance volume was falling.

This is not a contradiction in the ordinary sense. Oscillators can become oversold during a pullback even when the larger trend remains positive. The more concerning combination is the falling on-balance volume and the bearish trend readings: they imply that the recent advance toward the record close was not receiving equally strong volume confirmation.

Friday’s decline of 1.8% to $439.26, after the record close one session earlier, reinforces that near-term exhaustion reading. That was a bigger drop than the S&P 500’s 0.5% decline and the SPDR S&P Biotech ETF’s 1.4% decline, though Bristol Myers Squibb fell 2.4%. No post-announcement reaction to the full DeLLphi-305 data can be inferred yet because the market had not traded on the release.

Taken together, the readings show an intact longer-term trend with weaker short-term momentum going into Monday. They describe the setup; they do not say how the market will price the full data.

IMDELLTRA Is Growing Fast but Still Small Enough to Need Time

IMDELLTRA’s reported sales show genuine momentum. Revenue rose from $234 million in the fourth quarter of 2025 to $258 million in the first quarter of 2026 and $288 million in the second quarter. The second-quarter figure works out to an annualized run rate of approximately $1.15 billion.

That pace is strategically important, but the drug remains only about 3% of Amgen’s $10.05 billion second-quarter revenue. Even a successful first-line expansion would need several quarters of prescribing, regulatory execution, and treatment-center adoption before it could materially change the company’s consolidated growth rate.

The first-line opportunity is larger than the current second-line market because it reaches patients before many progress beyond initial therapy. Small cell lung cancer represents approximately 13% to 15% of more than 2.6 million lung cancers diagnosed worldwide each year, and DLL3 is expressed in roughly 85% to 96% of small cell lung cancer cases. Those figures support a large addressable population, but they do not establish how many patients will receive the combination or what pricing and access will look like.

The next hard commercial test arrives with Amgen’s third-quarter report on November 3. IMDELLTRA sales will matter more than another general statement about launch momentum. The key question is whether quarterly sales can continue rising at a pace consistent with first-line expansion before the regulatory pathway is complete.

The rest of the company gives the stock some support while investors wait. Second-quarter revenue grew 10%, adjusted earnings per share were $6.29 against a consensus estimate of approximately $5.62, and management raised 2026 revenue guidance to a range of $38.2 billion to $39.4 billion. Six growth drivers grew 26% and represented about 70% of product sales, helping offset the fact that IMDELLTRA is not yet large enough to carry the whole company.

Valuation and Analyst Targets Leave Less Room for a Routine Beat

At $439.26, AMGN carries a trailing price-to-earnings ratio of approximately 27 and a dividend yield of about 2.3%. Total debt is approximately $57.3 billion. At that multiple, the market is paying for current earnings plus future pipeline contribution, not just for today’s IMDELLTRA revenue base.

The analyst distribution is positive in breadth but cautious in price. Of 41 ratings, 22 are buys, 16 are holds, and three are sells. Yet the consensus price target is $403.79, roughly 8% below Friday’s close, with a median target of $410 and a high target of $500.

The gap between the clinical evidence and the analyst target is informative. Analysts may not yet have incorporated the full data, or they may be discounting the regulatory timeline, treatment burden, competitive response, and the fact that the result is not a head-to-head comparison. A target below the market price is not proof that the stock is overvalued, but it does mean the announcement needs to translate into future estimates rather than merely confirm an existing narrative.

The last eight quarters have produced earnings beats, which gives management some execution credibility. That record is part of what the current price already reflects. A strong clinical result can improve earnings several years out while failing to support a higher multiple immediately.

Long-Term Holders Support the Story but Are Not Signaling a Fresh Rush

The ownership evidence is steadier than the short-term trading evidence. PRIMECAP held 8.87 million shares, T. Rowe Price Equity Income held 1.87 million, and Ken Fisher held 1.58 million. Those positions show that established investment managers have exposure to Amgen’s longer-duration earnings and pipeline case.

They do not, however, establish that these investors bought in response to the DeLLphi-305 data. There were no reported insider trades in the last 45 days, and the only congressional transaction was a small House purchase in the $1,000 to $15,000 range on September 22. The positioning picture is therefore supportive but not catalytic.

That restraint fits the price action. The stock recovered strongly after the September low, but the falling volume-confirmation reading suggests that marginal buyers have not been pressing the move with the same force as the price itself. Neither the holder list nor insider activity points to new buying tied to the data.

Kavout’s composite score is 61, with a technical rating of 68 but an oscillator score of 37. The gap matches the rest of the evidence: a favorable longer-term trend with weaker short-term momentum.

What Comes Next

The clinical evidence makes IMDELLTRA a larger opportunity than it looked before the full data. A 0.42 overall-survival hazard ratio, nearly 80% one-year survival, and a move into first-line maintenance give the drug a path to a much larger patient population. The open questions are now about execution: regulatory timing, treatment-center adoption, side-effect management, and how quickly sales respond.

Four checkpoints will show whether the result becomes a commercial one:

1. Monday’s session (October 26). It is the first time the market trades on the full numbers. The stock goes in 1.8% below its record close and 16.9% above its September low.
2. A filing date. Amgen gave no submission or FDA timeline. Any date it announces turns the trial result into a launch calendar.
3. Third-quarter results on November 3. IMDELLTRA sales were $258 million in the first quarter and $288 million in the second. The third-quarter number is the next hard data point.
4. Analyst targets. The consensus target of $403.79 sits below the price. Whether targets move up after the full data will show how much of the result analysts had already modeled.

The olpasiran question stays open until outcomes data in 2027 or later. The September drop showed how much of Amgen’s value investors tie to that program. IMDELLTRA has made Amgen’s oncology business stronger, but the stock had already priced in much of the good news before investors saw the numbers.

---

Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.